ライフサイエンスコーパス: histamine receptor

1 but contrast with findings regarding the H2 histamine receptor.

2 identified and cloned a novel high-affinity histamine receptor.

3 that the AXOR35 receptor was a high-affinity histamine receptor.

4 , respective antagonists to lobster GABA and histamine receptors.

5 f histamine are inhibitory and exerted at H3 histamine receptors.

6 ude proteinase-activated receptor (PAR) 1 or histamine receptors.

7 ally mediated by histamine via H(2) and H(4) histamine receptors.

8 ic preoptic neurons by activating H3 subtype histamine receptors.

9 rate via activation of H(1) and H(2) subtype histamine receptors.

10 ounds that modulate the function of specific histamine receptors.

11 In animal models, histamine receptor 1 (HRH1) agonists and histamine recep

12 (EAE), mediated by T helper 1 (Th1) T cells, histamine receptor 1 and 2 (H1R and H2R) are present on

13 The perfusion of a histamine receptor 1 antagonist into the BF decreased bo

14 cell degranulation, but not by azelastine, a histamine receptor 1 antagonist, or by ketanserin, a ser

15 ed by platelet-activating factor receptor or histamine receptor 1 blockade.

16 ells, IgE-mediated mast cell activation, and histamine receptor 1 or 2 blockade on oral tolerance dev

17 Pretreatment with histamine receptor-1 antagonist, azelastine prevented th

18 Histamine receptor 2 (H(2)R)-deficient mice, histamine r

19 proinflammatory responses via activation of histamine receptor 2 (H2 R).

20 ing stress ulcer prophylaxis was $6,707 with histamine receptor-2 antagonist and $7,802 with proton p

21 Histamine receptor-2 antagonist or proton pump inhibitor

22 Histamine receptor-2 antagonist therapy appears to reduc

23 The probabilities that histamine receptor-2 antagonist was less costly and prov

24 r, resulting in a cost saving of $1,095 with histamine receptor-2 antagonist.

25 an absolute survival benefit of 0.006% with histamine receptor-2 antagonist.

26 infection showed a cost saving of $908 with histamine receptor-2 antagonists, but the survival benef

27 nd were not using a proton-pump inhibitor or histamine-receptor-2 (H2) blocker.

28 ls, histamine receptor 1 (HRH1) agonists and histamine receptor 3 (HRH3) antagonists decrease food in

29 gonists targeting different GPCRs, including histamine receptors, 5-HT (serotonin) receptors, muscari

30 We conclude that H1 histamine receptors activate ICat through coupling to Gi

31 on was also observed in the presence of H(2) histamine receptor activation and cholera toxin treatmen

32 ation of the Ca(2+) current mediated by H(2) histamine receptor activation.

33 tially dependent on nitric oxide (NO) and H1 histamine receptor activation.

34 es mediated by beta-adrenergic, but not H(2) histamine, receptor activation suggests that the inhibit

35 ns in the presence and absence of histamine, histamine receptor agonists and antagonists.

36 Herein, we profiled the pharmacology of histamine receptor agonists at the two most abundant hH3

37 s, including endogenous M3 muscarinic and H1 histamine receptor and expressed cysteinyl leukotriene t

38 he first ultrastructural localization of any histamine receptor and the first direct evidence that HR

39 ts, suggesting the presence of an ionotropic histamine receptor and the possible nonspecificity of cu

40 Crosstalk between histamine receptors and other membrane or nuclear recept

41 study was to determine the role of H1 and H2 histamine receptors and to examine a potential interacti

42 hput screening of compounds against multiple histamine receptors and, thus, facilitates drug discover

43 Histamine receptor 2 (H(2)R)-deficient mice, histamine receptors, and their signaling pathways were i

44 Consistently, the histamine receptor antagonist chlorpheniramine potently

45 The H1 histamine receptor antagonist chlorpheniramine, but not

46 Improgan, an analog of the histamine receptor antagonist cimetidine, produces highl

47 idine (100 microg; 5 microl; i.c.v.), the H2 histamine receptor antagonist with imidazoline receptor

48 c.v. preadministration of cimetidine, the H2-histamine receptor antagonist, failed to antagonize the

49 st cell stabilizer, doxantrazole, and the H1 histamine receptor antagonist, pyrilamine.

50 ii) Simultaneous administration of H1 and H2 histamine receptor antagonists (pyrilamine and famotidin

51 arnosine was found to be neuroprotective but histamine receptor antagonists had no effect on the exte

52 H1 and H2 histamine receptor antagonists, although developed many

53 Seven of nine trials of histamine-receptor antagonists showed a treatment-relate

54 anti-histaminergic effects, we show that H1 histamine receptors are not responsible for this effect

55 measure the affinity of compounds binding to histamine receptors are still routinely analyzed using a

56 ated, cannabinoid, opioid, cytokine, and new histamine receptors) are discussed.

57 The HDC/histamine/histamine receptor axis, ductular reaction, and biliary

58 e those for the analogous residues in the H1 histamine receptor but contrast with findings regarding

59 gonist cimetidine that does not act on known histamine receptors, but induces highly effective analge

60 mepyramine, a specific antagonist of the H1 histamine receptor, causes a delay in the birth of subse

61 low during whole body heating contains an H1 histamine receptor component but do not support an H2 hi

62 receptor component but do not support an H2 histamine receptor component.

63 at GRK2 is the principal kinase mediating H1 histamine receptor desensitization in HEK293 cells and s

64 Blockade of histamine receptors does not prevent NGF-induced hyperal

65 , little is known about its role or specific histamine receptors during the host response to bacteria

66 ch physically interacts with macrophages via histamine receptors, exhibits substantially diminished b

67 ntagonists specific for other members of the histamine receptor family had no effect in this assay fo

68 n the third intracellular loop of the murine histamine receptor H(1) (H(1)R) are candidates for Bphs,

69 otein-coupled receptors: H1, H2, H3, and H4 (histamine receptors; H(1-4)R).

70 Histamine receptor H1 (H1R) is a susceptibility gene in

71 rome (IBS) and evaluated if an antagonist of histamine receptor H1 (HRH1) could reduce symptoms of pa

72 The histamine receptor H1 antagonist diphenhydramine, the an

73 h selectivity against other sites, including histamine receptors H1, H2, and H4.

74 We demonstrate that iDCs express two active histamine receptors, H1 and H2.

75 The H1 histamine receptor (H1HR) is a member of the G protein-c

76 A clone containing the H1 histamine receptor (H1HR)-encoding gene was isolated fro

77 The histamine receptor H1R agonist, 2-pyridylethylamine, sup

78 ve study of the cross-talk between H1 and H2 histamine receptors (H1R and H2R) in U937 cells and Chin

79 The most recently discovered histamine receptor (H4) has emerged as a promising drug

80 Thus, histamine receptors have been actively pursued as therap

81 ion and activity of the four currently known histamine receptors; however, the relative protective or

82 Histidine decarboxylase (HDC) and histamine receptor (HR) expression were detected by qPCR

83 release of histamine, which acts on various histamine receptors (HR) 1-4, expressed by immune cells.

84 orld monkey retinas, we have been localizing histamine receptors (HR) and studying the effects of his

85 ets of these retinopetal axons, we localized histamine receptors (HR) in monkey and rat retinas by li

86 The presence and relative expression of histamine receptors HR1-4 and TLRs were determined as we

87 In prior work, type 3 histamine receptors (HR3) have been localized to the tip

88 t cells, and it exerts its functions through histamine receptors (HRs).

89 e describe here the protein expression of H4 histamine receptor in cells of the innate immune system,

90 2 (GRK2) regulates endogenously expressed H1 histamine receptor in human embryonic kidney 293 cells.

91 e glutamatergic marker Vglut2 and for the H1 histamine receptor in neurons excited by histamine.

92 Existing data on the expression of H(4) histamine receptor in the CNS are conflicting and inconc

93 amine a potential interaction between NO and histamine receptors in cutaneous active vasodilatation.

94 rther substantiated by the identification of histamine receptors in human sebaceous glands.

95 Here, we sought to define the necessity for histamine receptors in the pathology of anaphylaxis usin

96 this study, we investigated the role of the histamine receptors, in particular that of the histamine

97 Their ability to outcompete histamine receptors indicates that they suppress inflamm

98 the hypothesis that NFAT participates in H1 histamine receptor-induced interleukin-8 gene expression

99 lated by LTD4 yet had almost no effect on H1 histamine receptor internalization or signaling.

100 e research and the important applications of histamine receptor ligands, assays to measure the affini

101 The differences in histamine receptor localization may reflect the differen

102 DBu treatment produced similar effects on H2 histamine receptor-mediated ICa,L responses.

103 rmeability, gene and protein expression, and histamine receptor-mediated signaling.

104 Signaling through histamine receptors on dendritic cells (DCs) may be invo

105 In conclusion, our data show the presence of histamine receptors on sebocytes, demonstrate how an ant

106 tanding of the different aspects involved in histamine receptor pharmacology, which in turn will cont

107 In the future, particular histamine receptors, protease pathway molecules, and van

108 Likewise, biased signaling at histamine receptors seems to be a pharmacological featur

109 ed AXOR35, is most closely related to the H3 histamine receptor, sharing 37% protein sequence identit

110 patitis patients had increased HDC/histamine/histamine receptor signaling.

111 ese data demonstrate that GPCR105 is a novel histamine receptor structurally and pharmacologically re

112 Activation of each histamine receptor subtype (H(1)-H(4)) increased [Ca(2+)

113 ogical role suggest that GPCR105 is a fourth histamine receptor subtype (H(4)) and may be a therapeut

114 e neurone and involve activation of the same histamine receptor subtype, the histamine H1 receptor.

115 effect that was mimicked by either H1 or H3 histamine receptor subtype-specific agonists.

116 The four histamine receptor subtypes (H1R, H2R, H3R, and H4R) res

117 er than 1000-fold selectivity over the other histamine receptor subtypes and favorable pharmacokineti

118 s secretion, and that activation of all four histamine receptor subtypes can increase [Ca(2+)](i).

119 ntrast to: 1) analyze the specificity of the histamine receptor subtypes for different heterotrimeric

120 hion similar to that predicted for the other histamine receptor subtypes, there are also important di

121 algorithms showed enrichment of genes within histamine receptor (subtypes 1 and 2) signaling pathways

122 dentified ort as a candidate gene encoding a histamine receptor subunit on L1/L2.

123 There are currently four histamine receptors that have been cloned, all of which

124 the pharmacology and molecular mechanisms of histamine receptors that should be contemplated for opti

125 coupling of cardiac beta1-adrenergic and H2 histamine receptors to Gi/o mediated inhibitory response

126 sponses, including prostaglandin D synthase, histamine receptor type 1 (H1R), platelet activating fac

127 eprivation, and this effect was abolished by histamine receptor type I antagonist.

128 The mRNA expression of the histamine receptors was measured by real-time PCR.

129 he striatum also expresses a high density of histamine receptors, we hypothesized that released hista

130 identification and localization of this new histamine receptor will expand our understanding of the

131 al effects of histamine are mediated by four histamine receptors with distinct functions and distribu